Halozyme Therapeutics in (halo 1 08/15/28)
13F holders, Q4 2025 (December 31)6holders −2
1new positions
2sold out
$1.29avg. 13F price*
At the end of Q4 2025, 6 institutions reported holding Halozyme Therapeutics in (halo 1 08/15/28) in their 13F filings, down 2 from Q3 2025. 1 opened new positions and 2 sold out. The largest holders were Absolute Investment Advisers, LLC ($18.6M), Ofi Invest Asset Management ($7.7M) and State of Wisconsin Investment Board ($4.0M).
- Company
- Halozyme Therapeutics in (halo 1 08/15/28)
- CUSIP
- 40637HAF6
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $3.0M |
| Exits | 2 | $17K |
All 13F filers, Q3 2025 → Q4 2025: 2,405,893 shares bought and 12,100 shares sold, net +2,393,793 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Absolute Investment Advisers, LLC | 2.11% | No change | 14,000,000 | $18.6M |
| Ofi Invest Asset Management | 0.11% | No change | 6,800,000 | $7.7M |
| State of Wisconsin Investment Board | 0.01% | No change | 3,000,000 | $4.0M |
| Focus Partners Wealth | 0.00% | New | 2,295,000 | $3.0M |
| Bank of New York Mellon Corp | 0.00% | Add +22.0% | 610,000 | $810K |
| Loomis Sayles & Co. L P | 0.00% | Add +25.0% | 4,463 | $300K |
"% of holder's portfolio" is HALOZYME THERAPEUTICS IN (HALO 1 08/15/28)'s weight in each manager's 13F, not the share of Halozyme Therapeutics in (halo 1 08/15/28) the manager owns.